Bibliographic Details
| Title: |
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study |
| Authors: |
Wu, Yi-Long a, ∗, Kim, Hye Ryun b, Soo, Ross A. c, Zhou, Qing a, Akamatsu, Hiroaki d, Chang, Gee-Chen e, f, g, h, Chiu, Chao-Hua i, Hayashi, Hidetoshi j, Kim, Sang-We k, Goto, Yasushi l, Kato, Terufumi m, Zhou, Jianying n, Lee, Victor Ho-Fun o, Nishio, Makoto p, Han, Baohui q, Kim, Dong-Wan r, Lu, Shun r, Polli, Anna s, Martini, Jean-François t, Toffalorio, Francesca s, Wong, Chew Hooi u, Mok, Tony v |
| Source: |
In Journal of Thoracic Oncology February 2025 |
| Database: |
ScienceDirect |
